valsartan has been researched along with Fatty Liver in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (77.78) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Araki, E; Goto, R; Igata, M; Kawasaki, S; Kawashima, J; Kitano, S; Kondo, T; Matsumura, T; Matsuyama, R; Miyagawa, K; Motoshima, H; Ono, K | 1 |
| Chen, YH; Chen, YY; Qi, CJ; Yuan, L | 1 |
| Clark, SE; Ferrario, CM; Ibdah, JA; Li, W; Sowers, JR; Thyfault, JP; Uptergrove, GM; Wei, Y; Whaley-Connell, AT | 1 |
| Georgescu, EF; Ionescu, R; Mogoanta, L; Niculescu, M; Vancica, L | 1 |
| Chen, B; Du, G; Guo, J; Li, X; Qiang, G; Shi, L; Xuan, Q; Yang, H; Yang, X; Zhang, H; Zhang, L; Zhou, D; Zu, M | 1 |
| Kazdová, L; Kurtz, TW; Ogihara, T; Pravenec, M; Qi, NR; Sugimoto, K | 1 |
| Assy, N; Bersudsky, I; Grozovski, M; Hussein, O; Szvalb, S | 1 |
| Fujita, K; Inamori, M; Iwasaki, T; Kirikoshi, H; Maeyama, S; Mawatari, H; Nakajima, A; Nozaki, Y; Saito, S; Takahashi, H; Terauchi, Y; Wada, K; Yoneda, M | 1 |
| Clark, SE; Ferrario, CM; Ibdah, JA; Morris, EM; Sowers, JR; Thyfault, JP; Uptergrove, GM; Wei, Y; Whaley-Connell, AT | 1 |
1 trial(s) available for valsartan and Fatty Liver
| Article | Year |
|---|---|
Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis.
Topics: Alanine Transaminase; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Aspartate Aminotransferases; Benzimidazoles; Benzoates; Blood Pressure; Fatty Liver; Female; Humans; Hypertension; Liver Function Tests; Male; Middle Aged; Patient Selection; Telmisartan; Tetrazoles; Valine; Valsartan | 2009 |
8 other study(ies) available for valsartan and Fatty Liver
| Article | Year |
|---|---|
Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes.
Topics: Adamantane; Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Drug Therapy, Combination; Fatty Liver; Homeodomain Proteins; Inflammation; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Mice; Mice, Inbred C57BL; Nitriles; Phlorhizin; Pyrrolidines; Tetrazoles; Trans-Activators; Valine; Valsartan; Vildagliptin | 2013 |
[The effects of renin-angiotensin system blockade on the liver steatosis in rats on long-term high-fat diet].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Dietary Fats; Fatty Liver; Immunohistochemistry; Insulin Resistance; Ion Channels; Liver; Male; Mitochondrial Proteins; Perindopril; Rats; Rats, Wistar; Renin-Angiotensin System; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazoles; Time Factors; Transforming Growth Factor beta1; Uncoupling Protein 2; Valine; Valsartan | 2008 |
Oxidative stress-mediated mitochondrial dysfunction contributes to angiotensin II-induced nonalcoholic fatty liver disease in transgenic Ren2 rats.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Antioxidants; Blotting, Western; Cyclic N-Oxides; DNA, Mitochondrial; Fatty Acids; Fatty Liver; Gene Expression; Immunohistochemistry; Male; Microscopy, Electron, Transmission; Mitochondria; Oxidation-Reduction; Oxidative Stress; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Reverse Transcriptase Polymerase Chain Reaction; Spin Labels; Tetrazoles; Valine; Valsartan | 2009 |
Effect of valsartan on the pathological progression of hepatic fibrosis in rats with type 2 diabetes.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Progression; Fatty Liver; Gene Expression Regulation; Hepatocytes; In Situ Nick-End Labeling; Liver Cirrhosis, Experimental; Mitochondria, Liver; Non-alcoholic Fatty Liver Disease; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2012 |
Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis.
Topics: Adipocytes; Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Cell Count; Cell Size; Energy Metabolism; Fatty Liver; Gene Expression; Male; Mitochondria; Rats; Rats, Sprague-Dawley; Telmisartan; Tetrazoles; Valine; Valsartan; Weight Gain | 2006 |
Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease.
Topics: Animals; Anticholesteremic Agents; Azetidines; Choline Deficiency; Drug Therapy, Combination; Ezetimibe; Fats; Fatty Liver; Hypoglycemic Agents; Lipid Peroxidation; Liver; Male; Metformin; Oxidative Stress; Rats; Rats, Sprague-Dawley; Rosiglitazone; Tetrazoles; Thiazolidinediones; Tumor Necrosis Factor-alpha; Valine; Valsartan | 2006 |
Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats.
Topics: Actins; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Biomarkers; Blotting, Western; Collagen Type I; Disease Models, Animal; Disease Progression; Fatty Liver; Hypoglycemic Agents; Immunohistochemistry; Male; Pioglitazone; PPAR gamma; Rats; Rats, Inbred F344; Spectrophotometry; Telmisartan; Tetrazoles; Thiazolidinediones; Treatment Outcome; Valine; Valsartan | 2007 |
Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats.
Topics: Angiotensin II; Animals; Animals, Genetically Modified; Antihypertensive Agents; Antioxidants; Apoptosis; Blood Pressure; Cyclic N-Oxides; Disease Models, Animal; Fatty Liver; Lipid Peroxidation; Male; Oxidative Stress; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Renin; Renin-Angiotensin System; Spin Labels; Tetrazoles; Valine; Valsartan | 2008 |